Alex Lawson, Executive Director of Social Security Works, joins Ryan Grim to discuss the struggle to lower drug prices, the power of the pharmaceutical industry, and the future of drug price negotiation. They delve into corruption in healthcare policy, the battle for HR3, strategic blockades by politicians, and the impact of Medicare drug pricing negotiations on insulin and anti-retroviral drugs.
The inclusion of insulin on Medicare's list of drugs subject to price negotiations is a significant advancement in addressing high prescription drug costs.
The history of the law prohibiting Medicare from negotiating drug prices highlights the complex dynamics and challenges faced in lowering drug costs.
Deep dives
The Biden administration announces the first 10 drugs subject to price negotiations with Big Pharma
The Biden administration has revealed a list of the first 10 drugs that will be subject to price negotiations with Big Pharma under Medicare. This move comes as a major victory for healthcare reform advocates, as it includes short-acting insulin, a drug that has been the subject of a 20-year-long battle. The inclusion of insulin on the list serves as a significant step towards addressing the high cost of prescription drugs and providing relief to individuals who rely on this medication. With this announcement, a new federal agency dedicated to negotiating drug prices has also been established, amplifying efforts to lower drug costs.
The history of the law preventing Medicare from negotiating drug prices
The podcast delves into the history of the law that prohibited Medicare from negotiating drug prices and its impact on the cost of prescription drugs. The law, which originated in 2003, prevented Medicare from using its purchasing power to secure lower drug prices. This policy, known as the non-interference clause, has been heavily criticized for allowing pharmaceutical companies to maintain high drug prices. Despite Democratic opposition to this law, it remained in place due to Republican control and subsequent failed attempts during periods of Democratic control. However, with the recent victory in allowing Medicare to negotiate drug prices, progress is finally being made in addressing this long-standing issue.
The challenges faced in the fight to lower drug prices
The podcast highlights the challenges faced in the fight to lower drug prices. It discusses the influence of the pharmaceutical industry and the tactics employed to maintain high drug prices, such as lobbying and leveraging political power. The role of key policymakers, including members of Congress and the former Trump administration, is examined, shedding light on the complex dynamics that have hindered progress in this area. Despite these challenges, recent developments, such as the establishment of new policies and the inclusion of drugs like insulin in price negotiations, signal a turning point in the battle against high drug costs.
The potential impact of price negotiations on drug affordability
The podcast explores the potential impact of price negotiations on drug affordability. While the current focus is on Medicare negotiations with Big Pharma, there is optimism that these efforts will have a positive ripple effect throughout the healthcare system. By lowering the prices that Medicare pays for certain drugs, it sets a precedent that commercial payers can use to negotiate lower prices as well. This has the potential to benefit a wider range of individuals who rely on prescription medications and alleviate the financial burden on patients. While challenges and limitations remain, the progress made in price negotiations presents a significant step towards making essential medications more affordable for all.
Insulin, the lifesaving drug for tens of millions of Americans, is among the 10 drugs Medicare will negotiate for lower prices, by the power vested in the White House through the Inflation Reduction Act. This week on Deconstructed, Alex Lawson, executive director of Social Security Works, joins Ryan Grim to discuss the decadeslong struggle against the pharmaceutical lobby to lower drug prices and how the Biden administration secured Medicare drug pricing negotiations. Grim and Lawson discuss the pharmaceutical industry’s enormous power, their aggressive efforts to stop the legislation and water it down, the history of political infighting and betrayal that led to this moment, and what the future of drug price negotiation may look like.
If you’d like to support our work, go to theintercept.com/give, where your donation, no matter what the amount, makes a real difference.
And if you haven’t already, please subscribe to the show so you can hear it every week. And please go and leave us a rating or a review — it helps people find the show. If you want to give us additional feedback, email us at Podcasts@theintercept.com.